BCR and pachyonychia congenita: The next-generation AR inhibitor apalutamide combined with ongoing ADT has been shown to improve clinical outcomes and maintain HRQoL in patients with advanced disease [14, 15, 29, 30], but its treatment effect with or without ADT in BCR PC is unknown.